ArticleJournal of gastroenterology2026
Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucosal-associated invariant T (MAIT) cells have been implicated in several malignancies, but their role in pancreatic ductal adenocarcinoma (PDAC) remains unclear. This study aimed to characterize the presence, phenotype, and functional role of MAIT cells in PDAC and explore the underlying regulatory mechanisms.
methodsWe analyzed human PDAC tissue samples using single-cell RNA sequencing and flow cytometry to evaluate MAIT cell abundance and phenotype. Functional studies were performed in MR1-deficient (Mr1
resultsMAIT cells were significantly enriched in PDAC tissues and associated with poor patient survival. Further studies inMR1-deficient (Mr1
conclusionsOur findings reveal a novel TL1A-MAIT-CSF-1 axis that drives immunosuppression in PDAC by reprogramming innate immune responses. Targeting MAIT cells or TL1A signaling may represent a promising therapeutic strategy to improve immunotherapy efficacy in PDAC.
Indexed as
Identifiers
42340414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.